AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells
Figure 8
Effect of clofibrate and AS601245 in HepG-2 human liver cells. (a) Growth of HepG-2 cells treated with 5 μM clofibrate, 0,1 μM AS601245, and the association of these two compounds (Clofi + AS601245); (b) Western Blot analysis of PCNA detected in CaCo-2 cells treated with 5 μM clofibrate, 0.1 μM AS1245, and 5 μM clofibrate plus 0.1 μM AS601245 (Clofi + AS601245), collected at 24 hours after the treatment; (c) Western Blot analysis of p21, detected in CaCo-2 cells treated with 5 μM clofibrate, 0.1 μM AS1245, and 5 μM clofibrate plus 0.1 μM AS601245 (Clofi+AS601245), collected at 24 hours after the treatment; (d) Western Blot analysis of cyclin D1 detected in CaCo-2 cells treated with 5 μM clofibrate, 0.1 μM AS1245, and 5 μM clofibrate plus 0.1 μM AS601245 (Clofi + AS601245), collected at 24 hours after the treatment. Graphics represent the relative quantification of protein products performed by densitometric scanning. Data were normalized by using the β-actin signal, expressed as arbitrary densitometric units, and are the mean ± SD of three separate experiments from three different preparations for each condition. Variance analysis: *, ** versus control.
